EFEXOR 37.5 MG TABLETS

Main information

  • Trade name:
  • EFEXOR 37.5 MG TABLETS
  • Dosage:
  • 37.5 Milligram
  • Pharmaceutical form:
  • Tablets
  • Medicine domain:
  • Humans
  • Medicine type:
  • Allopathic drug

Documents

Localization

  • Available in:
  • EFEXOR 37.5 MG TABLETS
    Ireland
  • Language:
  • English

Status

  • Source:
  • HPRA - Health Products Regulatory Authority - Ireland
  • Authorization number:
  • PPA1151/076/001
  • Authorization date:
  • 21-11-2008
  • Last update:
  • 14-10-2016

Summary of Product characteristics: dosage, interactions, side effects

IRISHMEDICINESBOARDACTS1995AND2006

MEDICINALPRODUCTS(CONTROLOFPLACINGONTHEMARKET)REGULATIONS,2007

(S.I.No.540of2007)

PPA1151/076/001

CaseNo:2069197

TheIrishMedicinesBoardinexerciseofthepowersconferredonitbytheabovementionedRegulationsherebygrantsto

ImbatLimited

UnitL2,NorthRingBusinessPark,Santry,Dublin9

anauthorisation,subjecttotheprovisionsofthesaidRegulations,inrespectoftheproduct

Efexor37.5mgTablets,37.5Milligram

TheparticularsofwhicharesetoutinPartIandPartIIoftheattachedSchedule.Theauthorisationisalsosubjecttothegeneralconditionsas

maybespecifiedinthesaidRegulationsaslistedonthereverseofthisdocument.

Thisauthorisation,unlesspreviouslyrevoked,shallcontinueinforcefrom26/08/2009.

SignedonbehalfoftheIrishMedicinesBoardthis

________________

Irish Medicines Board

______________________________________________________________________________________________________________________

Date Printed 04/09/2009 CRN 2069197 page number: 1

PartII

SummaryofProductCharacteristics

1NAMEOFTHEMEDICINALPRODUCT

Efexor37.5mgTablets

2QUALITATIVEANDQUANTITATIVECOMPOSITION

Eachtabletcontains37.5mgofvenlafaxine(asvenlafaxinehydrochloride).

Alsocontains:lactose

Forafulllistofexcipients,seesection6.1.

3PHARMACEUTICALFORM

Tablet.

ProductimportedfromtheUK

Peachcoloured,shield-shapedtabletsimpressedwiththetabletstrength“37.5”andembossedwitha“W”ononeside,

andplainonthereverse.

4CLINICALPARTICULARS

4.1TherapeuticIndications

Treatmentofmajordepressiveepisodes.

Forpreventionofrecurrenceofmajordepressiveepisodes.

4.2Posologyandmethodofadministration

Majordepressiveepisodes

Therecommendedstartingdoseofimmediate-releasevenlafaxineis75mg/dayintwoorthreedivideddosestaken

withfood.Patientsnotrespondingtotheinitial75mg/daydosemaybenefitfromdoseincreasesuptoamaximumdose

of375mg/day.Dosageincreasescanbemadeatintervalsof2weeksormore.Ifclinicallywarrantedduetosymptom

severity,doseincreasescanbemadeatmorefrequentintervals,butnotlessthan4days.

Becauseoftheriskofdose-relatedadverseeffects,doseincrementsshouldbemadeonlyafteraclinicalevaluation(see

section4.4).Thelowesteffectivedoseshouldbemaintained.

Patientsshouldbetreatedforasufficientperiodoftime,usuallyseveralmonthsorlonger.Treatmentshouldbe

reassessedregularlyonacase-by-casebasis.Longer-termtreatmentmayalsobeappropriateforpreventionof

recurrenceofmajordepressiveepisodes(MDE).Inmostofthecases,therecommendeddoseinpreventionof

recurrenceofMDEisthesameastheoneusedduringthecurrentepisode.

Antidepressivemedicinalproductsshouldcontinueforatleastsixmonthsfollowingremission.

Useinelderlypatients

Nospecificdoseadjustmentsofvenlafaxineareconsiderednecessarybasedonpatientagealone.However,caution

shouldbeexercisedintreatingtheelderly(e.g.,duetothepossibilityofrenalimpairment,thepotentialforchangesin

neurotransmittersensitivityandaffinityoccurringwithaging).Thelowesteffectivedoseshouldalwaysbeused,and

patientsshouldbecarefullymonitoredwhenanincreaseinthedoseisrequired.

Useinchildrenandadolescentsundertheageof18years

Venlafaxineisnotrecommendedforuseinchildrenandadolescents.

Controlledclinicalstudiesinchildrenandadolescentswithmajordepressivedisorderfailedtodemonstrateefficacy

Irish Medicines Board

______________________________________________________________________________________________________________________

Date Printed 04/09/2009 CRN 2069197 page number: 2

Theefficacyandsafetyofvenlafaxineforotherindicationsinchildrenandadolescentsundertheageof18havenot

beenestablished.

Useinpatientswithhepaticimpairment

Inpatientswithmildandmoderatehepaticimpairment,ingenerala50%dosereductionshouldbeconsidered.

However,duetointer-individualvariabilityinclearance,individualisationofdosagemaybedesirable.

Therearelimiteddatainpatientswithseverehepaticimpairment.Cautionisadvised,andadosereductionbymore

than50%shouldbeconsidered.Thepotentialbenefitshouldbeweighedagainsttheriskinthetreatmentofpatients

withseverehepaticimpairment.

Useinpatientswithrenalimpairment

Althoughnochangeindosageisnecessaryforpatientswithglomerularfiltrationrate(GFR)between30-70ml/minute,

cautionisadvised.Forpatientsthatrequirehaemodialysisandinpatientswithsevererenalimpairment(GFR<30

ml/min),thedoseshouldbereducedby50%.Becauseofinter-individualvariabilityinclearanceinthesepatients,

individualisationofdosagemaybedesirable.

Withdrawalsymptomsseenondiscontinuationofvenlafaxine

Abruptdiscontinuationshouldbeavoided.Whenstoppingtreatmentwithvenlafaxine,thedoseshouldbegradually

reducedoveraperiodofatleastonetotwoweeksinordertoreducetheriskofwithdrawalreactions(seesections4.4

and4.8).Ifintolerablesymptomsoccurfollowingadecreaseinthedoseorupondiscontinuationoftreatment,then

resumingthepreviouslyprescribeddosemaybeconsidered.Subsequently,thephysicianmaycontinuedecreasingthe

dose,butatamoregradualrate.

Fororaluse.

Itisrecommendedthatvenlafaxineimmediate-releasetabletsbetakenwithfood,atapproximatelythesametimeeach

day.

Patientstreatedwithvenlafaxineimmediate-releasetabletsmaybeswitchedtovenlafaxineprolonged-releasecapsules

atthenearestequivalentdailydosage.Forexample,venlafaxineimmediate-releasetablets37.5mgtwicedailymaybe

switchedtovenlafaxineprolonged-releasecapsules75mgoncedaily.Individualdosageadjustmentsmaybenecessary.

4.3Contraindications

Hypersensitivitytotheactivesubstanceortoanyoftheexcipients.

Concomitanttreatmentwithirreversiblemonoamineoxidaseinhibitors(MAOIs)iscontraindicatedduetotheriskof

serotoninsyndromewithsymptomssuchasagitation,tremorandhyperthermia.Venlafaxinemustnotbeinitiatedforat

least14daysafterdiscontinuationoftreatmentwithanirreversibleMAOI.

Venlafaxinemustbediscontinuedforatleast7daysbeforestartingtreatmentwithanirreversibleMAOI(seesections

4.4and4.5).

4.4Specialwarningsandprecautionsforuse

Suicide/suicidalthoughtsorclinicalworsening

Depressionisassociatedwithanincreasedriskofsuicidalthoughts,self-harmandsuicide(suiciderelatedevents).This

riskpersistsuntilsignificantremissionoccurs.Asimprovementmaynotoccurduringthefirstfewweeksormoreof

treatment,patientsshouldbecloselymonitoreduntilsuchimprovementoccurs.Itisgeneralclinicalexperiencethatthe

riskofsuicidemayincreaseintheearlystagesofrecovery.

Otherpsychiatricconditionsforwhichvenlafaxineisprescribedcanalsobeassociatedwithanincreasedriskof

suicide-relatedevents.Inaddition,theseconditionsmaybeco-morbidwithmajordepressivedisorder.Thesame

precautionsobservedwhentreatingpatientswithmajordepressivedisordershouldthereforebeobservedwhentreating

patientswithotherpsychiatricdisorders.

Patientswithahistoryofsuicide-relatedevents,orthoseexhibitingasignificantdegreeofsuicidalideationpriorto

commencementoftreatment,areknowntobeatgreaterriskofsuicidalthoughtsorsuicideattempts,andshould

receivecarefulmonitoringduringtreatment.Ameta-analysisofplacebo-controlledclinicaltrialsofantidepressant

drugsinadultpatientswithpsychiatricdisordersshowedanincreasedriskofsuicidalbehaviourwithantidepressants

comparedtoplaceboinpatientslessthan25yearsold.

Irish Medicines Board

______________________________________________________________________________________________________________________

Date Printed 04/09/2009 CRN 2069197 page number: 3

treatmentandfollowingdosechanges.Patients(andcaregiversofpatients)shouldbealertedabouttheneedtomonitor

foranyclinicalworsening,suicidalbehaviourorthoughtsandunusualchangesinbehaviour,andtoseekmedical

adviceimmediatelyifthesesymptomspresent.

Useinchildrenandadolescentsunder18yearsofage

Efexorshouldnotbeusedinthetreatmentofchildrenandadolescentsundertheageof18years.Suicide-related

behaviours(suicideattemptandsuicidalthoughts)andhostility(predominantlyaggression,oppositionalbehaviourand

anger)weremorefrequentlyobservedinclinicaltrialsamongchildrenandadolescentstreatedwithantidepressants

comparedtothosetreatedwithplacebo.If,basedonclinicalneed,adecisiontotreatisneverthelesstaken,thepatient

shouldbecarefullymonitoredfortheappearanceofsuicidalsymptoms.Inaddition,long-termsafetydatainchildren

andadolescentsconcerninggrowth,maturationandcognitiveandbehaviouraldevelopmentarelacking.

Serotoninsyndrome

Aswithotherserotonergicagents,serotoninsyndrome,apotentiallylife-threateningcondition,mayoccurwith

venlafaxinetreatment,particularlywithconcomitantuseofotheragents,suchasMAO-inhibitors,thatmayaffectthe

serotonergicneurotransmittersystems(seesections4.3and4.5).

Serotoninsyndromesymptomsmayincludementalstatuschanges(e.g.,agitation,hallucinations,coma),autonomic

instability(e.g.,tachycardia,labilebloodpressure,hyperthermia),neuromuscularaberrations(e.g.,hyperreflexia,

incoordination)and/orgastrointestinalsymptoms(e.g.,nausea,vomiting,diarrhoea).

Narrow-angleglaucoma

Mydriasismayoccurinassociationwithvenlafaxine.Itisrecommendedthatpatientswithraisedintraocularpressure

orpatientsatriskforacutenarrow-angleglaucoma(angle-closureglaucoma)becloselymonitored.

Bloodpressure

Dose-relatedincreasesinbloodpressurehavebeencommonlyreportedwithvenlafaxine.Insomecases,severely

elevatedbloodpressurerequiringimmediatetreatmenthasbeenreportedinpostmarketingexperience.Allpatients

shouldbecarefullyscreenedforhighbloodpressureandpreexistinghypertensionshouldbecontrolledbeforeinitation

oftreatment.Bloodpressureshouldbereviewedperiodically,afterinitiationoftreatmentandafterdoseincreases.

Cautionshouldbeexercisedinpatientswhoseunderlyingconditionsmightbecompromisedbyincreasesinblood

pressure,e.g.,thosewithimpairedcardiacfunction.

Heartrate

Increasesinheartratecanoccur,particularlywithhigherdoses.Cautionshouldbeexercisedinpatientswhose

underlyingconditionsmightbecompromisedbyincreasesinheartrate.

Cardiacdiseaseandriskofarrhythmia

Venlafaxinehasnotbeenevaluatedinpatientswitharecenthistoryofmyocardialinfarctionorunstableheartdisease.

Therefore,itshouldbeusedwithcautioninthesepatients.

Inpostmarketingexperience,fatalcardiacarrhythmiashavebeenreportedwiththeuseofvenlafaxine,especiallyin

overdose.Thebalanceofrisksandbenefitsshouldbeconsideredbeforeprescribingvenlafaxinetopatientsathighrisk

ofseriouscardiacarrhythmia.

Convulsions

Convulsionsmayoccurwithvenlafaxinetherapy.Aswithallantidepressants,venlafaxineshouldbeintroducedwith

cautioninpatientswithahistoryofconvulsions,andconcernedpatientsshouldbecloselymonitored.Treatmentshould

bediscontinuedinanypatientwhodevelopsseizures.

Hyponatraemia

Casesofhyponatraemiaand/ortheSyndromeofInappropriateAntidiureticHormone(SIADH)secretionmayoccur

with

venlafaxine.Thishasmostfrequentlybeenreportedinvolume-depletedordehydratedpatients.Elderlypatients,

patientstakingdiuretics,andpatientswhoareotherwisevolume-depletedmaybeatgreaterriskforthisevent.

Abnormalbleeding

Irish Medicines Board

______________________________________________________________________________________________________________________

Date Printed 04/09/2009 CRN 2069197 page number: 4

membranebleeding,includinggastrointestinalhaemorrhage,maybeincreasedinpatientstakingvenlafaxine.Aswith

otherserotonin-reuptakeinhibitors,venlafaxineshouldbeusedcautiouslyinpatientspredisposedtobleeding,

includingpatientson

anticoagulantsandplateletinhibitors.

Serumcholesterol

Clinicallyrelevantincreasesinserumcholesterolwererecordedin5.3%ofvenlafaxine-treatedpatientsand0.0%of

placebo-treatedpatientstreatedforatleast3monthsinplacebo-controlledclinicaltrials.Measurementofserum

cholesterollevelsshouldbeconsideredduringlong-termtreatment.

Co-administrationwithweightlossagents

Thesafetyandefficacyofvenlafaxinetherapyincombinationwithweightlossagents,includingphentermine,havenot

beenestablished.Co-administrationofvenlafaxineandweightlossagentsisnotrecommended.Venlafaxineisnot

indicatedforweightlossaloneorincombinationwithotherproducts.

Mania/hypomania

Mania/hypomaniamayoccurinasmallproportionofpatientswithmooddisorderswhohavereceivedantidepressants,

includingvenlafaxine.Aswithotherantidepressants,venlafaxineshouldbeusedcautiouslyinpatientswithahistoryor

familyhistoryofbipolardisorder.

Aggression

Aggressionmayoccurinasmallnumberofpatientswhohavereceivedantidepressants,includingvenlafaxine.This

hasbeenreportedunderinitiation,dosechangesanddiscontinuationoftreatment.

Aswithotherantidepressants,venlafaxineshouldbeusedcautiouslyinpatientswithahistoryofaggression.

Discontinuationoftreatment

Withdrawalsymptomswhentreatmentisdiscontinuedarecommon,particularlyifdiscontinuationisabrupt(see

section4.8).Inclinicaltrials,adverseeventsseenontreatmentdiscontinuation(taperingandpost-tapering)occurredin

approximately35%ofpatientstreatedwithvenlafaxineand17%ofpatientstakingplacebo.

Theriskofwithdrawalsymptomsmaybedependentonseveralfactors,includingthedurationanddoseoftherapyand

therateofdosereduction.Dizziness,sensorydisturbances(includingparaesthesia),sleepdisturbances(including

insomniaandintensedreams),agitationoranxiety,nauseaand/orvomiting,tremorandheadachearethemost

commonlyreportedreactions.Generally,thesesymptomsaremildtomoderate;however,insomepatientstheymaybe

severeinintensity.Theyusuallyoccurwithinthefirstfewdaysofdiscontinuingtreatment,buttherehavebeenvery

rarereportsofsuchsymptomsinpatientswhohaveinadvertentlymissedadose.Generally,thesesymptomsareself-

limitingandusuallyresolvewithin2weeks,thoughinsomeindividualstheymaybeprolonged(2-3monthsormore).

Itisthereforeadvisedthatvenlafaxineshouldbegraduallytaperedwhendiscontinuingtreatmentoveraperiodof

severalweeksormonths,accordingtothepatient’sneeds(seesection4.2).

Akathisia/psychomotorrestlessness

Theuseofvenlafaxinehasbeenassociatedwiththedevelopmentofakathisia,characterisedbyasubjectively

unpleasantordistressingrestlessnessandneedtomoveoftenaccompaniedbyaninabilitytositorstandstill.Thisis

mostlikelytooccurwithinthefirstfewweeksoftreatment.Inpatientswhodevelopthesesymptoms,increasingthe

dosemaybedetrimental.

Drymouth

Drymouthisreportedin10%ofpatientstreatedwithvenlafaxine.Thismayincreasetheriskofcaries,andpatients

shouldbeadvisedupontheimportanceofdentalhygiene.

Lactoseintolerance

Patientswithrarehereditaryproblemsofgalactoseintolerance,theLapplactasedeficiencyorglucose-galactose

malabsorptionshouldnottakethismedicine.

Irish Medicines Board

______________________________________________________________________________________________________________________

Date Printed 04/09/2009 CRN 2069197 page number: 5

MonoamineOxidaseInhibitors(MAOI)

Irreversiblenon-selectiveMAOIs

Venlafaxinemustnotbeusedincombinationwithirreversiblenon-selectiveMAOIs.Venlafaxinemustnotbeinitiated

foratleast14daysafterdiscontinuationoftreatmentwithanirreversiblenon-selectiveMAOI.Venlafaxinemustbe

discontinuedforatleast7daysbeforestartingtreatmentwithanirreversiblenon-selectiveMAOI(seesections4.3and

4.4).

Reversible,selectiveMAO-Ainhibitor(moclobemide)

Duetotheriskofserotoninsyndrome,thecombinationofvenlafaxinewithareversibleandselectiveMAOI,suchas

moclobemide,isnotrecommended.FollowingtreatmentwithareversibleMAO-inhibitor,ashorterwithdrawalperiod

than14daysmaybeusedbeforeinitiationofvenlafaxinetreatment.Itisrecommendedthatvenlafaxineshouldbe

discontinuedforatleast7daysbeforestartingtreatmentwithareversibleMAOI(seesection4.4).

Reversible,non-selectiveMAOI(linezolid)

Theantibioticlinezolidisaweakreversibleandnon-selectiveMAOIandshouldnotbegiventopatientstreatedwith

venlafaxine(seesection4.4).

SevereadversereactionshavebeenreportedinpatientswhohaverecentlybeendiscontinuedfromanMAOIand

startedonvenlafaxine,orhaverecentlyhadvenlafaxinetherapydiscontinuedpriortoinitiationofanMAOI.These

reactionshaveincludedtremor,myoclonus,diaphoresis,nausea,vomiting,flushing,dizziness,andhyperthermiawith

featuresresemblingneurolepticmalignantsyndrome,seizures,anddeath.

Serotoninsyndrome

Aswithotherserotonergicagents,serotoninsyndromemayoccurwithvenlafaxinetreatment,particularlywith

concomitantuseofotheragentsthatmayaffecttheserotonergicneurotransmittersystem(includingtriptans,SSRIs,

SNRIs,lithium,sibutramine,tramadol,orSt.John'sWort[Hypericumperforatum]),withmedicinalagentswhich

impairmetabolismofserotonin(includingMAOIs),orwithserotoninprecursors(suchastryptophansupplements).

IfconcomitanttreatmentofvenlafaxinewithanSSRI,anSNRIoraserotoninreceptoragonist(triptan)isclinically

warranted,carefulobservationofthepatientisadvised,particularlyduringtreatmentinitiationanddoseincreases.The

concomitantuseofvenlafaxinewithserotoninprecursors(suchastryptophansupplements)isnotrecommended(see

section4.4).

CNS-activesubstances

TheriskofusingvenlafaxineincombinationwithotherCNS-activesubstanceshasnotbeensystematicallyevaluated.

Consequently,cautionisadvisedwhenvenlafaxineistakenincombinationwithotherCNS-activesubstances.

Ethanol

Venlafaxinehasbeenshownnottoincreasetheimpairmentofmentalandmotorskillscausedbyethanol.However,as

withallCNS-activesubstances,patientsshouldbeadvisedtoavoidalcoholconsumption.

Effectofothermedicinalproductsonvenlafaxine

Ketoconazole(CYP3A4inhibitor)

ApharmacokineticstudywithketoconazoleinCYP2D6extensive(EM)andpoormetabolisers(PM)resultedinhigher

AUCofvenlafaxine(70%and21%inCYP2D6PMandEMsubjects,respectively)andO-desmethylvenlafaxine(33%

and23%inCYP2D6PMandEMsubjects,respectively)followingadministrationofketoconazole.Concomitantuseof

CYP3A4inhibitors(e.g.,atazanavir,clarithromycin,indinavir,itraconazole,voriconazole,posaconazole,ketoconazole,

nelfinavir,ritonavir,saquinavir,telithromycin)andvenlafaxinemayincreaselevelsofvenlafaxineandO-

desmethylvenlafaxine.Therefore,cautionisadvisedifapatient’stherapyincludesaCYP3A4inhibitorandvenlafaxine

concomitantly.

Effectofvenlafaxineonothermedicinalproducts

Lithium

Serotoninsyndromemayoccurwiththeconcomitantuseofvenlafaxineandlithium(seeSerotoninsyndrome).

Diazepam

Irish Medicines Board

______________________________________________________________________________________________________________________

Date Printed 04/09/2009 CRN 2069197 page number: 6

desmethyldiazepam.DiazepamdoesnotappeartoaffectthepharmacokineticsofeithervenlafaxineorO-

desmethylvenlafaxine.Itisunknownwhetherapharmacokineticand/orpharmacodynamicinteractionwithother

benzodiazepinesexists.

Imipramine

Venlafaxinedidnotaffectthepharmacokineticsofimipramineand2-OH-imipramine.Therewasadose-dependent

increaseof2-OH-desipramineAUCby2.5to4.5-foldwhenvenlafaxine75mgto150mgdailywasadministered.

ImipraminedidnotaffectthepharmacokineticsofvenlafaxineandO-desmethylvenlafaxine.Theclinicalsignificance

ofthisinteractionisunknown.Cautionshouldbeexercisedwithco-administrationofvenlafaxineandimipramine.

Haloperidol

Apharmacokineticstudywithhaloperidolhasshowna42%decreaseintotaloralclearance,a70%increaseinAUC,

an88%increaseinCmax,butnochangeinhalf-lifeforhaloperidol.Thisshouldbetakenintoaccountinpatients

treatedwithhaloperidolandvenlafaxineconcomitantly.Theclinicalsignificanceofthisinteractionisunknown.

Risperidone

VenlafaxineincreasedtherisperidoneAUCby50%,butdidnotsignificantlyalterthepharmacokineticprofileofthe

totalactivemoiety(risperidoneplus9-hydroxyrisperidone).Theclinicalsignificanceofthisinteractionisunknown.

Metoprolol

Concomitantadministrationofvenlafaxineandmetoprololtohealthyvolunteersinapharmacokineticinteractionstudy

forbothmedicinalproductsresultedinanincreaseofplasmaconcentrationsofmetoprololbyapproximately30-40%

withoutalteringtheplasmaconcentrationsofitsactivemetabolite,-hydroxymetoprolol.Theclinicalrelevanceofthis

findinginhypertensivepatientsisunknown.Metoprololdidnotalterthepharmacokineticprofileofvenlafaxineorits

activemetabolite,O-desmethylvenlafaxine.Cautionshouldbeexercisedwithco-administrationofvenlafaxineand

metoprolol.

Indinavir

Apharmacokineticstudywithindinavirhasshowna28%decreaseinAUCanda36%decreaseinCmaxforindinavir.

IndinavirdidnotaffectthepharmacokineticsofvenlafaxineandO-desmethylvenlafaxine.Theclinicalsignificanceof

thisinteractionisunknown.

4.6Pregnancyandlactation

Pregnancy

Therearenoadequatedatafromtheuseofvenlafaxineinpregnantwomen.

Studiesinanimalshaveshownreproductivetoxicity(seesection5.3).Thepotentialriskforhumansisunknown.

Venlafaxinemustonlybeadministeredtopregnantwomeniftheexpectedbenefitsoutweighanypossiblerisk.

Aswithotherserotoninreuptakeinhibitors(SSRIs/SNRIs),discontinuationsymptomsmayoccurinthenewbornsif

venlafaxineisuseduntilorshortlybeforebirth.Somenewbornsexposedtovenlafaxinelateinthethirdtrimesterhave

developedcomplicationsrequiringtube-feeding,respiratorysupportorprolongedhospitalisation.Suchcomplications

canariseimmediatelyupondelivery.

ThefollowingsymptomsmaybeobservedinneonatesifthemotherhasusedanSSRI/SNRIlateinpregnancy:

irritability,tremor,hypotonia,persistentcrying,anddifficultyinsuckingorinsleeping.Thesesymptomsmaybedue

toeitherserotonergiceffectsorexposuresymptoms.Inthemajorityofcases,thesecomplicationsareobserved

immediatelyorwithin24hoursafterpartus.

Lactation

Venlafaxineanditsactivemetabolite,O-desmethylvenlafaxine,areexcretedinbreastmilk.Arisktothesucklingchild

cannotbeexcluded.Therefore,adecisiontocontinue/discontinuebreast-feedingortocontinue/discontinuetherapy

withEfexorshouldbemade,takingintoaccountthebenefitofbreast-feedingtothechildandthebenefitofEfexor

therapytothewoman.

Irish Medicines Board

______________________________________________________________________________________________________________________

Date Printed 04/09/2009 CRN 2069197 page number: 7

Anypsychoactivemedicinalproductmayimpairjudgment,thinking,andmotorskills.Therefore,anypatientreceiving

venlafaxineshouldbecautionedabouttheirabilitytodriveoroperatehazardousmachinery.

4.8Undesirableeffects

Themostcommonly(>1/10)reportedadversereactionsinclinicalstudieswerenausea,drymouth,headacheand

sweating(includingnightsweats).

Adversereactionsarelistedbelowbysystemorganclassandfrequency.

Frequenciesaredefinedas:verycommon( ≥1/10),common(≥1/100to<1/10),uncommon(≥1/1,000to<1/100),rare

≥1/10,000to<1/1,000),notknown(cannotbeestimatedfromtheavailabledata).

BodySystem Very

Common Common Uncommon Rare NotKnown

Haematological/

Lymphatic Ecchymosis,

Gastrointestinal

haemorrhage Mucousmembrane

bleeding,Prolonged

bleedingtime,

Thrombocytopaenia,

Blooddyscrasias,

(including

agranulocytosis,

aplasticanaemia,

neutropaeniaand

pancytopaenia)

Metabolic/

Nutritional Serumcholesterol

increased,Weight

loss Weightgain Abnormalliver

functiontests,

Hyponatraemia,

Hepatitis,

Syndromeof

Inappropriate

Antidiuretic

HormoneSecretion

(SIADH),Prolactin

increased

Nervous Drymouth

(10.0%),

Headache

(30.3%)* Abnormaldreams,

Decreasedlibido,

Dizziness,

Increasedmuscle

tonus(hypertonia),

Insomnia,

Nervousness,

Paresthesia,

Sedation,Tremor,

Confusion,

Apathy,

Hallucinations,

Myoclonus,

Agitation,

Impaired

coordinationand

balance Akathisia/

Psychomotor

restlessness,

Convulsion,

Manicreaction Neuroleptic

Malignant

Syndrome(NMS),

Serotonergic

syndrome,

Delirium,

Extrapyramidal

reactions(including

dystoniaand

dyskinaesia),

Tardive

dyskinaesia,

Suicidalideation

andbehaviours**

SpecialSenses Abnormalityof

accommodation,

Mydriasis,Visual

disturbance, Alteredtaste

sensation,

Tinnitus Angle-closure

glaucoma

Cardiovascular Hypertension,

Vasodilatation

(mostlyhot Postural

hypotension,

Syncope, Hypotension,QT

prolongation,

Irish Medicines Board

______________________________________________________________________________________________________________________

Date Printed 04/09/2009 CRN 2069197 page number: 8

*Inpooledclinicaltrials,theincidenceofheadachewas30.3%withvenlafaxineversus31.3%withplacebo.

**Casesofsuicidalideationandsuicidalbehaviourshavebeenreportedduringvenlafaxinetherapyorearlyafter

treatmentdiscontinuation(seesection4.4).

Discontinuationofvenlafaxine(particularlywhenabrupt)commonlyleadstowithdrawalsymptoms.

Dizziness,sensorydisturbances(includingparaethesia),sleepdisturbances(includinginsomniaandintensedreams),

agitationoranxiety,nauseaand/orvomiting,tremor,headacheandflusyndromearethemostcommonlyreported

flashes/flushes),

Palpitations Tachycardia fibrillation,

Ventricular

tachycardia

(includingtorsade

depointes)

Respiratory Yawning Pulmonary

eosinophilia

BodySystem Very

Common Common Uncommon Rare NotKnown

Digestive Nausea

(20.0%) Appetite

decreased

(anorexia),

Constipation,

Vomiting Bruxism,

Diarrhoea Pancreatitis

Skin Sweating

(including

night

sweats)

[12.2%] Rash,

Alopecia Erythema

multiforme,Toxic

epidermal

necrolysis,

Stevens-Johnson

syndrome,

Pruritus,Urticaria

Musculoskeletal Rhabdomyolysis

Urogenital Abnormal

ejaculation/orgas

m(males),

Anorgasmia,

Erectile

dysfunction

(impotence),

Urination

impaired(mostly

hesitancy),

Menstrual

disorders

associatedwith

increased

bleedingor

increased

irregularbleeding

(e.g.,

menorrhagia,

metrorrhagia),

Abnormal

orgasm

(females),

Urinary

retention

BodyasaWhole Asthenia

(fatigue),Chills Photosensitivit

Irish Medicines Board

______________________________________________________________________________________________________________________

Date Printed 04/09/2009 CRN 2069197 page number: 9

severeand/orprolonged.Itisthereforeadvisedthatwhenvenlafaxinetreatmentisnolongerrequired,gradual

discontinuationbydosetaperingshouldbecarriedout(seesections4.2and4.4).

Paediatricpatients

Ingeneral,theadversereactionprofileofvenlafaxine(inplacebo-controlledclinicaltrials)inchildrenandadolescents

(ages6to17)wassimilartothatseenforadults.Aswithadults,decreasedappetite,weightloss,increasedblood

pressure,andincreasedserumcholesterolwereobserved(seesection4.4).

Inpaediatricclinicaltrialstheadversereactionsuicidalideationwasobserved.Therewerealsoincreasedreportsof

hostilityand,especiallyinmajordepressivedisorder,self-harm.

Particularly,thefollowingadversereactionswereobservedinpaediatricpatients:abdominalpain,agitation,dyspepsia,

ecchymosis,epistaxis,andmyalgia.

4.9Overdose

Inpostmarketingexperience,overdosewithvenlafaxinewasreportedpredominantlyincombinationwithalcohol

and/orothermedicinalproducts.Themostcommonlyreportedeventsinoverdoseincludetachycardia,changesinlevel

ofconsciousness(rangingfromsomnolencetocoma),mydriasis,convulsion,andvomiting.Otherreportedevents

includeelectrocardiographicchanges(e.g.,prolongationofQTinterval,bundlebranchblock,QRSprolongation),

ventriculartachycardia,bradycardia,hypotension,vertigo,anddeath.

Publishedretrospectivestudiesreportthatvenlafaxineoverdosagemaybeassociatedwithanincreasedriskoffatal

outcomescomparedtothatobservedwithSSRIantidepressantproducts,butlowerthanthatfortricyclic

antidepressants.Epidemiologicalstudieshaveshownthatvenlafaxinetreatedpatientshaveahigherburdenofsuicide

riskfactorsthanSSRIpatients.Theextenttowhichthefindingofanincreasedriskoffataloutcomescanbeattributed

tothetoxicityofvenlafaxineinoverdosage,asopposedtosomecharacteristicsofvenlafaxine-treatedpatients,isnot

clear.Prescriptionsforvenlafaxineshouldbewrittenforthesmallestquantityofthemedicinalproductconsistentwith

goodpatientmanagementinordertoreducetheriskofoverdose.

Recommendedtreatment

Generalsupportiveandsymptomaticmeasuresarerecommended;cardiacrhythmandvitalsignsmustbemonitored.

Whenthereisariskofaspiration,inductionofemesisisnotrecommended.Gastriclavagemaybeindicatedif

performedsoonafteringestionorinsymptomaticpatients.Administrationofactivatedcharcoalmayalsolimit

absorptionoftheactivesubstance.Forceddiuresis,dialysis,hemoperfusionandexchangetransfusionareunlikelytobe

ofbenefit.Nospecificantidotesforvenlafaxineareknown.

5PHARMACOLOGICALPROPERTIES

Efexorisastructurallynovelantidepressantwhichischemicallyunrelatedtotricyclic,tetracyclic,orotheravailable

antidepressantagents.Itisaracematewithtwoactiveenantiomers.

5.1Pharmacodynamicproperties

Pharmacotherapeuticgroup:Otherantidepressants-ATCcode:NO6AX16.

Themechanismofvenlafaxine'santidepressantactioninhumansisbelievedtobeassociatedwithitspotentiationof

neurotransmitteractivityinthecentralnervoussystem.Preclinicalstudieshaveshownthatvenlafaxineanditsmajor

metabolite,O-desmethylvenlafaxine(ODV),areinhibitorsofserotoninandnoradrenalinereuptake.Venlafaxinealso

weaklyinhibitsdopamineuptake.Venlafaxineanditsactivemetabolitereduce-adrenergicresponsivenessafterboth

acute(singledose)andchronicadministration.VenlafaxineandODVareverysimilarwithrespecttotheiroverall

actiononneurotransmitterreuptakeandreceptorbinding.

Venlafaxinehasvirtuallynoaffinityforratbrainmuscarinic,cholinergic,H1-histaminergicor1-adrenergicreceptors

invitro.Pharmacologicalactivityatthesereceptorsmayberelatedtovarioussideeffectsseenwithother

antidepressantmedicinalproducts,suchasanticholinergic,sedativeandcardiovascularsideeffects.

Venlafaxinedoesnotpossessmonoamineoxidase(MAO)inhibitoryactivity.

Irish Medicines Board

______________________________________________________________________________________________________________________

Date Printed 04/09/2009 CRN 2069197 page number: 10

Majordepressiveepisodes

Theefficacyofvenlafaxineimmediate-releaseasatreatmentformajordepressiveepisodeswasdemonstratedinfive

randomised,double-blind,placebo-controlled,short-termtrialsrangingfrom4to6weeksduration,fordosesupto375

mg/day.Theefficacyofvenlafaxineprolonged-releaseasatreatmentformajordepressiveepisodeswasestablishedin

twoplacebo-controlled,short-termstudiesfor8and12weeksduration,whichincludedadoserangeof75to225

mg/day.

Inonelonger-termstudy,adultoutpatientswhohadrespondedduringan8-weekopentrialonvenlafaxineprolonged-

release(75,150,or225mg)wererandomisedtocontinuationoftheirsamevenlafaxineprolonged-releasedoseorto

placebo,forupto26weeksofobservationforrelapse.

Inasecondlonger-termstudy,theefficacyofvenlafaxineinpreventionofrecurrentdepressiveepisodesfora12-

monthperiodwasestablishedinaplacebo-controlleddouble-blindclinicaltrialinadultoutpatientswithrecurrent

majordepressiveepisodeswhohadrespondedtovenlafaxinetreatment(100to200mg/day,onab.i.d.schedule)onthe

lastepisodeofdepression.

5.2Pharmacokineticproperties

Venlafaxineisextensivelymetabolised,primarilytotheactivemetabolite,O-desmethylvenlafaxine(ODV).Mean±

SDplasmahalf-livesofvenlafaxineandODVare5±2hoursand11±2hours,respectively.Steady-stateconcentrations

ofvenlafaxineandODVareattainedwithin3daysoforalmultiple-dosetherapy.VenlafaxineandODVexhibitlinear

kineticsoverthedoserangeof75mgto450mg/day.

Absorption

Atleast92%ofvenlafaxineisabsorbedfollowingsingleoraldosesofimmediate-releasevenlafaxine.Absolute

bioavailabilityis40%to45%duetopresystemicmetabolism.Afterimmediate-releasevenlafaxineadministration,the

peakplasmaconcentrationsofvenlafaxineandODVoccurin2and3hours,respectively.Followingtheadministration

ofvenlafaxineprolonged-releasecapsules,peakplasmaconcentrationsofvenlafaxineandODVareattainedwithin5.5

hoursand9hours,respectively.Whenequaldailydosesofvenlafaxineareadministeredaseitheranimmediate-release

tabletorprolonged-releasecapsule,theprolonged-releasecapsuleprovidesaslowerrateofabsorption,butthesame

extentofabsorptioncomparedwiththeimmediate-releasetablet.Fooddoesnotaffectthebioavailabilityofvenlafaxine

andODV.

Distribution

VenlafaxineandODVareminimallyboundattherapeuticconcentrationstohumanplasmaproteins(27%and30%,

respectively).Thevolumeofdistributionforvenlafaxineatsteady-stateis4.4±1.6L/kgfollowingintravenous

administration.

Metabolism

Venlafaxineundergoesextensivehepaticmetabolism.Invitroandinvivostudiesindicatethatvenlafaxineis

biotransformedtoitsmajoractivemetabolite,ODV,byCYP2D6.Invitroandinvivostudiesindicatethatvenlafaxine

ismetabolisedtoaminor,lessactivemetabolite,N-desmethylvenlafaxine,byCYP3A4.Invitroandinvivostudies

indicatethatvenlafaxineisaweakinhibitorofCYP2D6.VenlafaxinedidnotinhibitCYP1A2,CYP2C9,orCYP3A4.

Elimination

Venlafaxineanditsmetabolitesareexcretedprimarilythroughthekidneys.Approximately87%ofavenlafaxinedose

isrecoveredintheurinewithin48hoursaseitherunchangedvenlafaxine(5%),unconjugatedODV(29%),conjugated

ODV(26%),orotherminorinactivemetabolites(27%).Mean±SDplasmasteady-stateclearancesofvenlafaxineand

ODVare1.3±0.6L/h/kgand0.4±0.2L/h/kg,respectively.

Specialpopulations

Ageandgender

SubjectageandgenderdonotsignificantlyaffectthepharmacokineticsofvenlafaxineandODV.

CYP2D6extensive/poormetabolisers

PlasmaconcentrationsofvenlafaxinearehigherinCYP2D6poormetabolisersthanextensivemetabolisers.Because

Irish Medicines Board

______________________________________________________________________________________________________________________

Date Printed 04/09/2009 CRN 2069197 page number: 11

differentvenlafaxinedosingregimensforthesetwogroups.

Patientswithhepaticimpairment

InChild-PughA(mildlyhepaticallyimpaired)andChild-PughB(moderatelyhepaticallyimpaired)subjects,

venlafaxineandODVhalf-liveswereprolongedcomparedtonormalsubjects.Theoralclearanceofbothvenlafaxine

andODVwasreduced.Alargedegreeofintersubjectvariabilitywasnoted.Therearelimiteddatainpatientswith

severehepaticimpairment(seesection4.2).

Patientswithrenalimpairment

Indialysispatients,venlafaxineeliminationhalf-lifewasprolongedbyabout180%andclearancereducedbyabout

57%comparedtonormalsubjects,whileODVeliminationhalf-lifewasprolongedbyabout142%andclearance

reducedbyabout56%.Dosageadjustmentisnecessaryinpatientswithsevererenalimpairmentandinpatientsthat

requirehaemodialysis(seesection4.2).

5.3Preclinicalsafetydata

Studieswithvenlafaxineinratsandmicerevealednoevidenceofcarcinogenesis.Venlafaxinewasnotmutagenicina

widerangeofinvitroandinvivotests.

Animalstudiesregardingreproductivetoxicityhavefoundinratsadecreaseinpupweight,anincreaseinstillborn

pups,andanincreaseinpupdeathsduringthefirst5daysoflactation.Thecauseofthesedeathsisunknown.These

effectsoccurredat30mg/kg/day,4timesthehumandailydoseof375mgofvenlafaxine(onanmg/kgbasis).Theno-

effectdoseforthesefindingswas1.3timesthehumandose.Thepotentialriskforhumansisunknown.

ReducedfertilitywasobservedinastudyinwhichbothmaleandfemaleratswereexposedtoODV.Thisexposurewas

approximately1to2timesthatofahumanvenlafaxinedoseof375mg/day.Thehumanrelevanceofthisfindingis

unknown.

6PHARMACEUTICALPARTICULARS

6.1Listofexcipients

Microcrystallinecellulose

Lactose

Sodiumstarchglycollate

Magnesiumstearate

Yellowironoxide(E172)

Brownironoxide(E172)

6.2Incompatibilities

Notapplicable.

6.3ShelfLife

Theshelflifeexpirydateofthisproductshallbethedateshownonthecontainerandouterpackageoftheproducton

themarketinthecountryoforigin.

6.4Specialprecautionsforstorage

Donotstoreabove30°C.Storeinoriginalpackage.

Irish Medicines Board

______________________________________________________________________________________________________________________

Date Printed 04/09/2009 CRN 2069197 page number: 12

Overlabelledcardboardcartoncontainingcalendarblisterstrips.Packsize56.

6.6Specialprecautionsfordisposalofausedmedicinalproductorwastematerialsderivedfrom

suchmedicinalproductandotherhandlingoftheproduct

Nospecialrequirements.

7ParallelProductAuthorisationHolder

ImbatLimited

UnitL2

NorthRingBusinessPark

Santry

Dublin9

8ParallelProductAuthorisationNumber

PPA1151/76/1

9DATEOFFIRSTAUTHORISATION/RENEWALOFTHEAUTHORISATION

DateofFirstAuthorisation:21stNovember2008

10DATEOFREVISIONOFTHETEXT

Irish Medicines Board

______________________________________________________________________________________________________________________

Date Printed 04/09/2009 CRN 2069197 page number: 13